Disc Medicine, Inc. is under investigation by the Rosen Law Firm for potential securities claims following the FDA's rejection of its bitopertin drug application on February 13, 2026. The FDA cited uncertainties requiring additional evidence, causing Disc Medicine's stock to fall 22% that day. The law firm is preparing a class action to recover investor losses, offering compensation without upfront fees. Investors who purchased Disc Medicine securities may join the class action by contacting the Rosen Law Firm.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
B&M European Value Retail's first-quarter update has divided analysts, with Deutsche Bank upgrading the stock to 'hold' citing stabilizing profit margins and a sensible turnaround strategy by new CEO Tjeerd Jegen. Deutsche Bank raised its profit fore...
Telo Genomics announced positive interim results from a clinical study analyzing blood samples of multiple myeloma patients to predict relapse risk using 3D telomere analysis. The test showed strong predictive accuracy, potentially offering a less in...
Meta now notifies parents if their teen talks about suicide or self-harm with its AI chatbot and is developing a feature to contact emergency services if risk is detected. This move addresses concerns about AI chatbots handling crisis conversations, ...
NTG Clarity Networks announced new purchase orders and contract renewals totaling about CAD 16.6 million, reflecting strong demand for its software development and digital transformation services. This includes $2.3 million from a real estate client ...
